Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies
Recombinant therapeutic proteins, of which monoclonal antibodies (mAbs) represent the largest market, are used to treat diseases including cancer, blood and immune disorders. The cost and complexity of large-scale production and purification of mAbs translates to high cost of therapy. We hypothesise...
Main Authors: | Antepowicz, A, Tan, A, Pringle, A, Hyde, S, Gill, D |
---|---|
格式: | Conference item |
出版: |
Mary Ann Liebert Inc
2016
|
相似書籍
-
Development of lung and muscle factories to deliver therapeutic monoclonal antibodies
由: Antepowicz, A
出版: (2018) -
431. Lung antibody factory for passive immunisation against influenza
由: Tan, T, et al.
出版: (2016) -
Lentiviral-mediated expression of monoclonal antibodies in the lung to protect against influenza
由: Du, Y, et al.
出版: (2020) -
Antibody gene transfer for prophylaxis of respiratory syncytial virus (RSV) infection
由: Antepowicz, A, et al.
出版: (2018) -
The lung as a factory to produce secreted intrapulmonary and circulatory proteins
由: Paul-Smith, M, et al.
出版: (2017)